Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ELAN Stock Forecast 2026-2027
$22.61
Current Price
$11.29B
Market Cap
Buy 15
Hold 1
Sell 1
Wall St Analyst Ratings
Distance to ELAN Price Targets
+41.5%
To High Target of $32.00
+32.7%
To Median Target of $30.00
-11.5%
To Low Target of $20.00
ELAN Price Momentum
-2.7%
1 Week Change
-5.7%
1 Month Change
+154.3%
1 Year Change
-0.1%
Year-to-Date Change
-18.4%
From 52W High of $27.72
+171.4%
From 52W Low of $8.33
📊 TOP ANALYST CALLS
Did ELAN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Elanco is one of their latest high-conviction picks.
Latest ELAN Stock Price Targets & Analyst Predictions
Based on our analysis of 16 Wall Street analysts, ELAN has a bullish consensus with a median price target of $30.00 (ranging from $20.00 to $32.00). The overall analyst rating is Strong Buy (8.9/10). Currently trading at $22.61, the median forecast implies a 32.7% upside. This outlook is supported by 15 Buy, 1 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Chris Schott at JP Morgan, projecting a 41.5% upside. Conversely, the most conservative target is provided by Balaji Prasad at Barclays, suggesting a 11.5% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ELAN Analyst Ratings
15
Buy
1
Hold
1
Sell
ELAN Price Target Range
Low
$20.00
Average
$30.00
High
$32.00
Current: $22.61
Latest ELAN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ELAN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 15, 2026 | Citigroup | Daniel Grosslight | Buy | Initiates | $30.00 |
| Feb 25, 2026 | Morgan Stanley | Erin Wright | Equal-Weight | Maintains | $24.00 |
| Feb 25, 2026 | Keybanc | Steve Dechert | Overweight | Maintains | $29.00 |
| Feb 24, 2026 | Leerink Partners | Daniel Clark | Outperform | Maintains | $30.00 |
| Feb 19, 2026 | JP Morgan | Chris Schott | Overweight | Maintains | $28.00 |
| Jan 22, 2026 | Piper Sandler | David Westenberg | Overweight | Upgrade | $30.00 |
| Dec 18, 2025 | Morgan Stanley | Erin Wright | Equal-Weight | Maintains | $22.00 |
| Dec 9, 2025 | Barclays | Glen Santangelo | Overweight | Initiates | $30.00 |
| Nov 21, 2025 | Keybanc | Steve Dechert | Overweight | Initiates | $27.00 |
| Nov 6, 2025 | UBS | Andrea Alfonso | Buy | Maintains | $27.00 |
| Oct 20, 2025 | UBS | Andrea Alfonso | Buy | Maintains | $25.00 |
| Oct 7, 2025 | JP Morgan | Chris Schott | Overweight | Upgrade | $24.00 |
| Sep 24, 2025 | Stifel | Jonathan Block | Buy | Maintains | $23.00 |
| Aug 11, 2025 | Piper Sandler | David Westenberg | Neutral | Maintains | $18.00 |
| Aug 8, 2025 | UBS | Andrea Alfonso | Buy | Maintains | $19.00 |
| Jul 23, 2025 | UBS | Andrea Alfonso | Buy | Maintains | $18.00 |
| Jul 17, 2025 | Leerink Partners | Daniel Clark | Outperform | Upgrade | $18.00 |
| Jul 2, 2025 | Stifel | Jonathan Block | Buy | Maintains | $17.00 |
| Jun 26, 2025 | William Blair | Brandon Vazquez | Outperform | Upgrade | $N/A |
| May 19, 2025 | Stifel | Jonathan Block | Buy | Maintains | $16.00 |
Elanco Animal Health Incorporated (ELAN) Competitors
The following stocks are similar to Elanco based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Elanco Animal Health Incorporated (ELAN) Financial Data
Elanco Animal Health Incorporated has a market capitalization of $11.29B with a P/E ratio of 377.1x. The company generates $4.71B in trailing twelve-month revenue with a -4.9% profit margin.
Revenue growth is +12.2% quarter-over-quarter, while maintaining an operating margin of +2.3% and return on equity of -3.7%.
Valuation Metrics
Market Cap
$11.29B
Enterprise Value
$15.67B
P/E Ratio
377.1x
PEG Ratio
0.1x
Price/Sales
2.5x
Growth & Margins
Revenue Growth (YoY)
+12.2%
Gross Margin
+51.5%
Operating Margin
+2.3%
Net Margin
-4.9%
EPS Growth
+12.2%
Financial Health
Cash/Price Ratio
+4.8%
Current Ratio
2.2x
Debt/Equity
67.9x
ROE
-3.7%
ROA
+1.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Elanco Animal Health Incorporated (ELAN) Business Model
About Elanco Animal Health Incorporated
What They Do
Develops innovative animal health pharmaceutical products.
Business Model
The company generates revenue by creating and delivering a range of pharmaceutical products aimed at preventing and treating diseases in both companion animals and livestock. It serves veterinarians, farmers, and pet owners, leveraging its extensive research-driven expertise to address significant animal health challenges.
Additional Information
With a history dating back to 1954, Elanco operates in over 90 countries and earns more than half of its revenue from international markets. Its commitment to research and sustainable practices positions it as a key player in enhancing animal welfare and supporting food security and public health.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
9,400
CEO
Mr. Jeffrey N. Simmons
Country
United States
IPO Year
2018
Website
www.elanco.comElanco Animal Health Incorporated (ELAN) Latest News & Analysis
Latest News
Elanco Confirms Date and Conference Call for First Quarter 2026 Financial Results Announcement
6 days ago
Quick Summary
Elanco Animal Health (NYSE: ELAN) will release its Q1 2026 financial results on May 6, 2026, followed by a conference call for investors and media.
Why It Matters
Elanco's upcoming Q1 2026 results and conference call may impact its stock price, reflecting investor sentiment and expectations for future performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Elanco Animal Health launched the Advantage™ Collar for Dogs, offering four months of protection against fleas, ticks, and mosquitoes. It fits any size dog and is priced under $25.
Why It Matters
Elanco's launch of the Advantage™ Collar enhances its product lineup, potentially increasing market share and revenue, appealing to pet owners, and strengthening brand loyalty.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Elanco Animal Health (ELAN) shares rose significantly with above-average trading volume, but recent earnings estimate revisions may not lead to immediate price increases.
Why It Matters
Elanco's share surge indicates positive investor sentiment, but high trading volumes with stagnant earnings revisions suggest potential price volatility ahead.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Elanco Animal Health (ELAN) presented at the 2026 KeyBanc Capital Markets Healthcare Forum, indicating ongoing engagement with investors and stakeholders.
Why It Matters
Elanco's presentation at a major healthcare forum highlights its strategic direction and potential growth, influencing investor sentiment and stock performance in the animal health sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Elanco Animal Health Incorporated (ELAN) presented at the Barclays 28th Annual Global Healthcare Conference, highlighting its strategic initiatives and performance.
Why It Matters
Elanco's presentation at a major healthcare conference signals its strategic direction and potential growth, influencing investor sentiment and stock performance in the animal health sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Elanco Animal Health Incorporated (ELAN) Presents at Leerink Global Healthcare Conference 2026 Transcript
1 month ago
Quick Summary
Elanco Animal Health Incorporated (ELAN) presented at the Leerink Global Healthcare Conference 2026, discussing its business outlook and strategies.
Why It Matters
Elanco's presentation at a major healthcare conference signals strategic insights and potential growth opportunities, impacting investor confidence and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About ELAN Stock
What is Elanco Animal Health Incorporated's (ELAN) stock forecast for 2026?
Based on our analysis of 16 Wall Street analysts, Elanco Animal Health Incorporated (ELAN) has a median price target of $30.00. The highest price target is $32.00 and the lowest is $20.00.
Is ELAN stock a good investment in 2026?
According to current analyst ratings, ELAN has 15 Buy ratings, 1 Hold ratings, and 1 Sell ratings. The stock is currently trading at $22.61. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ELAN stock?
Wall Street analysts predict ELAN stock could reach $30.00 in the next 12 months. This represents a 32.7% increase from the current price of $22.61. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Elanco Animal Health Incorporated's business model?
The company generates revenue by creating and delivering a range of pharmaceutical products aimed at preventing and treating diseases in both companion animals and livestock. It serves veterinarians, farmers, and pet owners, leveraging its extensive research-driven expertise to address significant animal health challenges.
What is the highest forecasted price for ELAN Elanco Animal Health Incorporated?
The highest price target for ELAN is $32.00 from Chris Schott at JP Morgan, which represents a 41.5% increase from the current price of $22.61.
What is the lowest forecasted price for ELAN Elanco Animal Health Incorporated?
The lowest price target for ELAN is $20.00 from Balaji Prasad at Barclays, which represents a -11.5% decrease from the current price of $22.61.
What is the overall ELAN consensus from analysts for Elanco Animal Health Incorporated?
The overall analyst consensus for ELAN is bullish. Out of 16 Wall Street analysts, 15 rate it as Buy, 1 as Hold, and 1 as Sell, with a median price target of $30.00.
How accurate are ELAN stock price projections?
Stock price projections, including those for Elanco Animal Health Incorporated, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 7:57 AM UTC